Design, synthesis and biological evaluation of 3-(2-aminooxazol-5-yl)-2H-chromen-2-one derivatives

BMC Chemistry

Table 2 In vitro antimicrobial activity of the synthesized compounds

Comp.	Antimicrobial screening (MIC = µM)
Comp.	SA	EC	BS	PA	SE	CA	AN
1	61.5	61.5	61.5	30.8	61.5	30.8	30.8
2	72.2	72.2	72.2	36.1	36.1	36.1	72.2
3	14.8	14.8	59.2	59.2	59.2	29.6	29.6
4	63.5	63.5	31.7	63.5	63.5	31.7	31.7
5	59.2	59.2	59.2	29.6	59.2	29.6	29.6
6	71.3	71.3	71.3	35.6	17.8	35.6	17.8
7	34.6	34.6	34.6	69.2	69.2	34.6	34.6
8	34.9	34.9	17.5	69.8	69.8	34.9	69.8
9	77.6	77.6	38.8	38.8	77.6	38.8	38.8
10	36.5	36.5	73.0	36.5	73.0	36.5	36.5
11	69.2	34.6	34.6	34.6	69.2	69.2	69.2
12	34.6	34.6	34.6	34.6	69.2	34.6	69.2
13	63.5	63.5	63.5	31.7	63.5	31.7	63.5
14	69.1	69.1	69.1	17.3	69.1	34.5	69.1
15	65.1	65.1	32.6	32.6	65.1	32.6	65.1
Cefadroxil	17.2	17.2	17.2	17.2	17.2	–	–
Fluconazole	–	–	–	–	–	20.4	20.4

SA, Staphylococcus aureus, EC, Escherichia coli; BS, Bacillus subtilis; PA, Pseudomonas aeruginosa; SE, Salmonella enterica; CA, Candida albicans; AN, Aspergillus niger

ISSN: 2661-801X